TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32736540
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus chemotherapy (4 cycles of 3 weeks of intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide according to histologic subtype)
Study: 32736540
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus chemotherapy
Study: 35437881
Drug: Topical oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxygen therapy and standard of care (TOT/SOC)
Study: 36103844
Drug: Su Jok
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Su Jok seed therapy
Study: 36738762
Drug: Golimumab monotherapy
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab monotherapy
Study: 33234578
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment strategy using monoclonal antibodies combined with optimally sequenced chemotherapy
Study: 34146120
Drug: TRE cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRE cream (0.05% tretinoin cream)
Study: 35859328
Drug: PEG-rhG-CSF as
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF as primary prophylactic therapy
Study: 35859328
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rhG-CSF administered when white blood cell count was <2.0 × 10^9/L or absolute neutrophil count <1.0 × 10^9/L)
Study: 38190136
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy only)
Study: 32189364
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy after lamivudine resistance
Study: 33946085
Drug: Fostemsavir 600
Normalized name: fostemsavir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir 600 mg twice daily with optimized background therapy (OBT)
Study: 32750261
Drug: DTaP-IPV-Hib-HepB vaccine
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-Hib-HepB vaccine
Study: 32750261
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (PENTACEL™ or INFANRIX™ hexa)
Study: 36029653
Drug: FP/bevacizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/bevacizumab + atezolizumab (800 mg 60-min i.v. infusion q2 weeks)
Study: 32861217
Drug: Esketamine 84
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 84 mg nasal spray twice weekly for 4 weeks with standard of care
Study: 32861217
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray twice weekly for 4 weeks with standard of care
Study: 33856570
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous teriparatide (TPD) 20 mcg
Study: 33856570
Drug: Cyclic teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cyclic teriparatide (TPD) followed by raloxifene (RLX) 60 mg
Study: 35278336
Drug: Control (implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (implant surgery alone)
Study: 34072293
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (2.3 g omega-3 daily)
Study: 33118519
Drug: Urea ointment
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea ointment
Study: 35243421
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied lactobacilli, daily application for 8 weeks.
Study: 36176927
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Chinese herbal fumigation sitz-bath and red ointment
Study: 36176927
Drug: Red ointment
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ointment therapy
Study: 34170932
Drug: FPG ADA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG ADA definition (5.6-6.9 mmol/l)
Study: 32481390
Drug: Extralevator abdominoperineal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extralevator abdominoperineal resection (L-ELAPE)
Study: 34228836
Drug: Dipyrone 30
Normalized name: dipyrone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 30 mg/kg q12h
Study: 34228836
Drug: Dipyrone 30
Normalized name: dipyrone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 30 mg/kg q8h
Study: 34228836
Drug: Dipyrone 60
Normalized name: dipyrone 606 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 60 mg/kg q8h
Study: 34228836
Drug: Dipyrone 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 90 mg/kg q12h
Study: 32075695
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (TMI) adjunct to standard care (30-min group-based smoking cessation counseling and nicotine patches)
Study: 32075695
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (30-min group-based smoking cessation counseling and nicotine patches)
Study: 32014846
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise and health coaching intervention including 1 weekly supervised exercise session.
Study: 37522226
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments combined
Study: 35022952
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (500 mg)
Study: 36047381
Drug: Empowering Community
Normalized name: Empowered Choice
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Empowering Community Pharmacists program (monthly resources/reminders + educational webinar)
Study: 36047381
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly reminders only)
Study: 33413291
Drug: IND/GLY/MF 150/50/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY/MF 150/50/80 μg (ICS medium-dose)
Study: 33413291
Drug: IND/GLY/MF 150/50/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY/MF 150/50/160 μg (ICS high-dose)
Study: 33413291
Drug: IND/GLY/MF (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY/MF (both doses)
Study: 32106885
Drug: Intervention package
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention package consisting of structured sessions of behavior activation, problem-solving treatment, and parenting skills training delivered by primary maternal health care providers and supported by a 'neighborhood mother'.
Study: 32933470
Drug: Ultrasound-guided great
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided great auricular nerve block (GANB) with 2 ml of 0.25% ropivacaine
Study: 34385093
Drug: Processed Aloe
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Processed Aloe Vera Gel (PAG)
Study: 32804414
Drug: Synthesized dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthesized dynamic treatment regimes (DTRs)
Study: 36001752
Drug: CNI (Calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI (Calcineurin Inhibitors)
Study: 32077231
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg ZGN-1061
Study: 32077231
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg ZGN-1061
Study: 35596803
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg/day
Study: 33634687
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF) standard dose of 1000 mg once daily for 2 months (group 1)
Study: 33634687
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF) double dose of 1000 mg twice daily for 1 month and then 1000 mg once daily for 1 month (group 2)
Study: 33735635
Drug: Omeprazole capsule
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsule
Study: 32178701
Drug: Astragalus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus injection
Study: 32178701
Drug: Salvia Miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia Miltiorrhiza injection
Study: 32178701
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including treatment and control)
Study: 34830950
Drug: Ultra-hypofractionated RT/stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-hypofractionated RT/stereotactic body RT with focal RT dose escalation on intraprostatic tumor sides
Study: 36289039
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard radiation therapy workflow)
Study: 33527809
Drug: Azilsartan 40
Normalized name: azilsartan 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan 40 mg
Study: 33527809
Drug: Azilsartan 80
Normalized name: azilsartan 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan 80 mg
Study: 35932889
Drug: Immediate telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate telephone smoking cessation intervention (TSI) support with appropriate pharmacotherapy for 6 weeks
Study: 33521132
Drug: L-carnitine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine therapy
Study: 32830463
Drug: Oral Janus
Normalized name: Ricinus nanus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Janus kinase 1 (JAK1) inhibitor abrocitinib (dose range 10-200 mg)
Study: 36242741
Drug: Vidofludimus calcium
Normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidofludimus calcium (45 mg for 14 days)
Study: 33823960
Drug: Food-related behavioral
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-related behavioral activation (F-BA) therapy with placebo supplements
Study: 33823960
Drug: Multi-nutrient supplements
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient supplements (omega-3 fatty acids and a multi-vitamin)
Study: 33823960
Drug: F-BA therapy
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-BA therapy with multi-nutrient supplements
Study: 35760971
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion of piperacillin/tazobactam
Study: 35760971
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin/tazobactam
Study: 34398235
Drug: Varenicline vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline vs Nicotine patches
Study: 33060783
Drug: Duodenal acid
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal acid infusion
Study: 33997052
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment prior to restoration
Study: 33044435
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise (150 min·wk‐1)
Study: 33044435
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (300 min·wk‐1)
Study: 36942507
Drug: Placebo (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multiple dose)
Study: 35299272
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic medicines (IHM) in centesimal potencies
Study: 34182967
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with a diode laser (810 nm wavelength, 100 mW power output, 6.29 J/cm2 energy density) applied on days 0, 7, 14, and 21 after loading the canine retraction forces.
Study: 34677118
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacological treatment only)
Study: 33932574
Drug: PHARM-DC intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PHARM-DC intervention (pharmacist-directed transitional care including medication reconciliation, medication review, increased communication, patient education and counseling)
Study: 34218277
Drug: Particle Beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particle Beam Therapy (PBT)
Study: 33111932
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at rates of 0, 4.0, 8.0, and 16 g L‐1 under three soil water conditions (50% and 100% of soil water retention capacity and complete submergence in a water blade of 5.0 cm)
Study: 32241356
Drug: Custom cantilever
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Custom cantilever appliance producing 100 g of force for buccal translation
Study: 34855690
Drug: Stimulants
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulants
Study: 35475308
Drug: 75 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg/kg eptacog beta initial dose regimen (IDR)
Study: 35475308
Drug: 225 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 μg/kg eptacog beta initial dose regimen (IDR)
Study: 32151752
Drug: Brief advice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief advice (BA) to exercise alone (minimal treatment control condition)
Study: 32147068
Drug: Edible glucose
Normalized name: edible oyster preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edible glucose 30% (2 ml, n = 40)
Study: 39223470
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia
Study: 33326140
Drug: Athlete Biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Athlete Biological Passport
Study: 35298833
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 2% (5 g/daily) for 24 weeks
Study: 34106922
Drug: Levo-Praziquantel (L-PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levo-Praziquantel (L-PZQ) ODT 150 mg
Study: 34106922
Drug: Racemate Praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemate Praziquantel (Rac-PZQ) ODT 150 mg
Study: 34106922
Drug: PZQ 600
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ 600 mg formulation (PZQ-Cesol) crushed and dispersed in water
Study: 34446332
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT), performed once a week for 12 weeks on quadriceps femoris muscles.
Study: 32318831
Drug: Air/water spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air/water spray (control group)
Study: 34229861
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (1.5 mg.kg-1 bolus over 3 minutes, followed by continuous infusion at 2 mg.kg-1.h-1)
Study: 34229861
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline solution (control group)
Study: 34564685
Drug: Intra-alveolar administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-alveolar administration of dexamethasone 4 mg
Study: 34564685
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of dexamethasone
Study: 32111230
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate solution
Study: 38152462
Drug: Dextromethorphan (DXM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DXM) 400 mg/70 kg
Study: 36227615
Drug: Capecitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1000 mg/m2 twice daily for 14 days every 3 weeks for 8 cycles)
Study: 36227615
Drug: Observation following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation following CCRT (100 mg/m2 cisplatin every 3 weeks for 2 to 3 cycles)
Study: 35366853
Drug: Beraprost sodium
Normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium (BPS) 60 μg/day and aspirin 100 mg/day
Study: 34533102
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (RT) twice-weekly for 10 weeks
Study: 34399432
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OACs)
Study: 35677972
Drug: Ribavirin aerosol
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin aerosol (50 mg/ml, 10 ml total volume)
Study: 35677972
Drug: Ribavirin aerosol
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin aerosol (50 mg/ml, 20 ml total volume)
Study: 35677972
Drug: Ribavirin aerosol
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin aerosol (100 mg/ml, 10 ml total volume)
Study: 35677972
Drug: Ribavirin aerosol
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin aerosol (100 mg/ml, 20 ml total volume)
Study: 34535979
Drug: Telemonitoring intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemonitoring intervention with four daily short text messages for 30 days
Study: 34665055
Drug: Aggressive heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive heating with three different heaters (compressed-air blower heater, intravenous fluid heating, heating bed)
Study: 35674747
Drug: Low-dose triple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose triple combination therapy
Study: 33097936
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (∼4 g/d)
Study: 33097936
Drug: ALA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA supplementation (∼4 g/d)
Study: 32029008
Drug: Ibuprofen sustained-release
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen sustained-release capsules
Study: 35576498
Drug: Rapid Syllable
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Syllable Transition Treatment (ReST)
Study: 35576498
Drug: Blended intervention
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended intervention (combination of ReST and AAC)
Study: 32651146
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Control group, n = 36)
Study: 32349074
Drug: Calibrated esophageal
Normalized name: CALIBRATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calibrated esophageal pressure measurements during pneumoperitoneum-Trendelenburg and PEEP administration
Study: 32932396
Drug: Buffered and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered and nonbuffered saline solutions
Study: 35731881
Drug: Conversations focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversations focusing on disagreement (e.g., why each supports their own party)
Study: 32845114
Drug: Roflumilast cream
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast cream 0.5%
Study: 36745371
Drug: Roflumilast cream
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast cream 0.15%
Study: 34645147
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy + glutamine
Study: 34645147
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy + glutamine
Study: 35130547
Drug: IQP-LU-104 high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: IQP-LU-104 high dose (104HD)
Study: 35130547
Drug: IQP-LU-104 low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IQP-LU-104 low dose (104LD)
Study: 32732353
Drug: Denosumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (all dose groups)
Study: 35385827
Drug: Vi polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide (ViPS) vaccine
Study: 34549356
Drug: Succinylated gelatin
Normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylated gelatin (4%) (GEL)
Study: 34549356
Drug: Compound sodium
Normalized name: SODIUM CHLORIDE 6 g in 1 L / SODIUM LACTATE 3.22 g in 1 L / POTASSIUM CHLORIDE 400 mg in 1 L / CALCIUM CHLORIDE 270 mg in 1 L INTRAVENOUS INJECTION, SOLUTION [COMPOUND SODIUM LACTATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound sodium lactate (CSL)